UNSPSC 51273808: Benzethonium/benzocaine/glycerin/polyethylene glycol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT400. This VA Drug Class (OT400) classifies this compound as belonging to the group ANALGESICS, TOPICAL OTIC.

UNSPSC 51273808 Benzethonium/benzocaine/glycerin/polyethylene glycol is a Commodity code that, based on recent state and local opportunities, covers pharmaceutical and over-the-counter products including naloxone, safe drug deactivation systems, and generic multi-source medications supplied through established pharmaceutical distribution channels. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances coordinating procurement across member jurisdictions. The scope reflects actual purchasing of finished pharmaceutical products and health-related supplies rather than raw chemical ingredients, with vendors typically required to supply through authorized wholesalers, maintain FDA compliance and cGMP certifications, hold appropriate insurance coverage including commercial general liability and professional liability policies, and meet electronic data interchange and supply-chain security standards.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs and state pharmacy benefit initiatives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. MMCAP's structure illustrates the multistate cooperative model increasingly common in pharmaceutical procurement, where vendors must establish relationships with authorized wholesalers and accept administrative fees (3 percent in MMCAP's case) as part of the contracted supply chain.